Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT04389840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04389840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2/3
Overall status
Terminated
Start date
July 8, 2020
Completion date
May 20, 2021
Enrollment
27 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, coronavirus disease 2019 (covid-19), severe acute respiratory syndrome coronavirus 2 (sars-cov-2)